耐阻性高血压和阻塞性睡眠呼吸暂停
Grace Oscullo1,2,3, Martino F Pengo4,5, Jose Daniel Gómez-Olivas1,2,3
1Pneumology Department, Hospital Universitario y Politécnico La Fe. Valencia. Spain.
Journal of hypertension
|October 2, 2025
概括
耐药性高血压 (RfH) 与睡眠呼吸暂停综合征 (OSA) 有关. 用CPAP治疗OSA可显著降低RfH患者的血压,改善心血管风险.
科学领域:
- 心脏病学 心脏病学
- 睡眠医学 睡眠医学
- 高血压研究 高血压研究
背景情况:
- 耐药性高血压 (RfH) 是一种严重的高血压形式,具有较高的心血管风险,影响0.5-1%的高血压患者.
- 睡眠呼吸暂停综合征 (OSA),以睡眠期间气道阻塞为特征,在全球非常普遍.
- RfH和OSA都涉及同情神经系统过度激活,这表明共享的病理生理路径.
研究的目的:
- 为了研究耐火性高血压和睡眠呼吸暂停综合征之间的临床关系.
- 探索OSA治疗对RfH患者血压控制的影响.
主要方法:
- 观察性研究和临床试验检查RfH患者.
- 在RfH人群中评估OSA患病率.
- 在RfH患者中对OSA进行持续正气道压力 (CPAP) 治疗后降低血压的评估.
主要成果:
- 在被诊断为RfH的患者中观察到高患病率的OSA (80-90%) .
- 持续的正气道压力 (CPAP) 对OSA的治疗表明,在患有RfH的患者中,血压显著降低,通常为8-10 mmHg.
- 这表明OSA可能会导致高血压患者的治疗耐药性.
结论:
- 睡眠呼吸暂停综合征是耐性高血压患者常见的并发症.
- 用CPAP有效治疗OSA可以改善血压控制,并可能降低这一患者群体的心血管风险.
更多相关视频
相关概念视频
Sleep Apnea
481
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
481
Heart Failure VI: Adjunct Therapies
261
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
261
Hypertension II: Pathophysiology
795
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
795
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
Hypertension I: Introduction
743
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
743
Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.5K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.5K


